BioNTech SE ADR (BNTX)
NASDAQ: BNTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BNTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $20.07B
- EPS (TTM)
- -$6.83
- Dividend yield
- None
- Ex-dividend date
- Jun 2, 2022
- 52-week range
- 79.52 – 124.00
- Day range
- 80.27 – 82.87
- Volume / Avg
- 1.71M / 1.08M
- Beta
- —
- Shares outstanding
- 247.93M
52-week range
BNTX stock today
Shares of BioNTech (BNTX) finished lower on Nov 20 at $80.96, a drop of 0.52% or $0.42 per share, versus the S&P 500's 3.70% decline. At this level, BNTX sits near the bottom of its 52-week range of $79.52 to $124.00: 34.7% below the high, set on Jan 22, 2026 and 1.8% above the low. BNTX is down 15.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 15.3%.
BioNTech has posted a net loss over the last twelve months (EPS of -$6.83), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About BioNTech
Company profileBioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Ugur Sahin M.D.
- Headquarters
- Mainz
- Employees
- 7,807
- IPO year
- 2019
- Website
- biontech.de
Analyst forecast
ForecastConsensus (21 analysts)
buy
Avg. price target
$112.14+38.51%
- Strong buy 1
- Buy 13
- Hold 7
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $-0.14 vs $0.85
- Surprise
- -116.47%
Dividends
Dividend history- Annual dividend
- $0.00
- Last payment
- $2.11
- Ex-dividend date
- Jun 2, 2022
BNTX news
All BNTX news- Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027NasdaqMRNA, MRK, BMY, BNTX
- Moderna: Can the Vaccine Business Fund Its Next Phase of Growth?NasdaqMRNA, PFE, MRK, BNTX
- BioNTech: Priority Review Voucher Purchase Hints At Much Needed Approval ShotSeeking Alpha
- MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock?NasdaqMRNA, PFE, MRK, BNTX
- BioNTech vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?NasdaqBNTX, VRTX
- BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027NasdaqBNTX, MRNA
- Axsome Therapeutics vs. BioNTech: Which Healthcare Stock Is a Better Buy for 2027?NasdaqAXSM, BNTX
- BioNTech SE 2026 Q3 - Results - Earnings Call PresentationSeeking Alpha
BioNTech peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| EXELExelixis Inc. | 64.63 | -1.82% | $15.77B | vs BNTX |
| NBIXNeurocrine Biosciences Inc. | 150.57 | -3.84% | $15.24B | vs BNTX |
| TECHBio-Techne Corp | 72.67 | -0.04% | $11.42B | vs BNTX |
| RGENRepligen Corporation | 163.81 | -3.81% | $10.47B | vs BNTX |
| HALOHalozyme Therapeutics Inc. | 91.35 | -1.82% | $10.41B | vs BNTX |
| QGENQiagen N.V. | 49.30 | -0.66% | $10.18B | vs BNTX |
| KYMRKymera Therapeutics Inc. | 115.31 | -3.42% | $9.84B | vs BNTX |
| KRYSKrystal Biotech Inc. | 308.89 | -2.19% | $9.15B | vs BNTX |
Indexes, lists and sector
BioNTech stock FAQ
What is BioNTech's stock price today?
BNTX last traded at $80.96 as of Nov 20, 4:00 PM EST, down 0.52% on the day. Prices are delayed at least 15 minutes.
Does BioNTech pay a dividend?
Yes. BioNTech pays $0.00 per share annually. The most recent dividend of $2.11 had an ex-dividend date of Jun 2, 2022.
Who is BioNTech's CEO?
Dr. Ugur Sahin M.D. is the chief executive officer of BioNTech SE ADR, which has about 7,807 employees.
What is the BNTX 52-week high?
The 52-week high for BNTX is $124.00 and the 52-week low is $79.52. The stock is currently 34.7% below its high.